Cart
sales@molnova.com
Desoxo-narchinol A
CAS No. 53859-06-6
Desoxo-narchinol A ( )
Catalog No. M31583 CAS No. 53859-06-6
Desoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1863 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameDesoxo-narchinol A
-
NoteResearch use only, not for human use.
-
Brief DescriptionDesoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.
-
DescriptionDesoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number53859-06-6
-
Formula Weight192.3
-
Molecular FormulaC12H16O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Bendazac
Bendazac is an anticataract drug. It may act by preventing protein denaturation.
-
Cyclic MKEY
MKEY, a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, has been shown to protect against atherosclerosis and aortic aneurysm formation by mediating inflammation, but whether it modulates neuroinflammation and brain injury has not been studied.
-
(-)-Lyoniresinol
(-)-Lyoniresinol has antioxidant activity.
